{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:52:00Z","timestamp":1775602320514,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38996-5","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:58:24Z","timestamp":1772459904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive machine learning identifies anoikis signatures predicting therapeutic resistance and survival in gastric cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Fangchao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghuan","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"38996_CR1","doi-asserted-by":"publisher","unstructured":"Global cancer statistics 2022. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - Bray\u2009\u2013\u20092024 - CA: A Cancer Journal for Clinicians - Wiley Online Library [Internet]. [cited 2024 Sep 4]. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"issue":"7","key":"38996_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3390\/jcm12072636","volume":"12","author":"Y Narita","year":"2023","unstructured":"Narita, Y. & Muro, K. Updated immunotherapy for gastric cancer. J. Clin. Med. 12 (7), 2636 (2023).","journal-title":"J. Clin. Med."},{"issue":"3","key":"38996_CR3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/curroncol29030131","volume":"29","author":"A H\u00f6gner","year":"2022","unstructured":"H\u00f6gner, A. & Moehler, M. Immunotherapy in gastric cancer. Curr. Oncol. 29 (3), 1559\u20131574 (2022).","journal-title":"Curr. Oncol."},{"issue":"1","key":"38996_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15384047.2022.2038002","volume":"23","author":"T Yoshida","year":"2022","unstructured":"Yoshida, T. et al. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. Cancer Biol. Ther. 23 (1), 191\u2013200 (2022).","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"38996_CR5","first-page":"83","volume":"123","author":"L Stanek","year":"2022","unstructured":"Stanek, L., Gurlich, R., Musil, Z., Havluj, L. & Whitley, A. Monitoring EBV infection, MSI, PDL-1 expression, Her-2\/neu amplification as a biomarker for PD-1 Inhibition in gastric cancer. Bratisl Lek Listy. 123 (2), 83\u201386 (2022).","journal-title":"Bratisl Lek Listy"},{"issue":"16_suppl","key":"38996_CR6","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1200\/JCO.2022.40.16_suppl.4062","volume":"40","author":"J Gong","year":"2022","unstructured":"Gong, J. et al. A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G\/GEJ cancer. JCO 40 (16_suppl), 4062\u20134062 (2022).","journal-title":"JCO"},{"issue":"10","key":"38996_CR7","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.3390\/curroncol30100672","volume":"30","author":"A D\u00e9silets","year":"2023","unstructured":"D\u00e9silets, A., Elkhoury, R., Gebai, A. & Tehfe, M. Current and emerging role of monoclonal Antibody-Based First-Line treatment in advanced Gastro-Esophageal and gastric cancer. Curr. Oncol. 30 (10), 9304\u20139316 (2023).","journal-title":"Curr. Oncol."},{"key":"38996_CR8","unstructured":"Understanding and targeting anoikis in metastasis for cancer therapies - PubMed [Internet]. [cited 2024 Sep 5]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36453448\/"},{"key":"38996_CR9","doi-asserted-by":"publisher","first-page":"626577","DOI":"10.3389\/fonc.2021.626577","volume":"11","author":"FO Adeshakin","year":"2021","unstructured":"Adeshakin, F. O. et al. Mechanisms for modulating Anoikis resistance in cancer and the relevance of metabolic reprogramming. Front. Oncol. 11, 626577 (2021).","journal-title":"Front. Oncol."},{"issue":"6","key":"38996_CR10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1158\/0008-5472.CAN-19-0743","volume":"80","author":"BL Eckhardt","year":"2020","unstructured":"Eckhardt, B. L. et al. Activation of canonical BMP4-SMAD7 signaling suppresses breast cancer metastasis. Cancer Res. 80 (6), 1304\u20131315 (2020).","journal-title":"Cancer Res."},{"issue":"19","key":"38996_CR11","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.3390\/cancers14194791","volume":"14","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Anoikis-Associated lung cancer metastasis: mechanisms and therapies. Cancers (Basel). 14 (19), 4791 (2022).","journal-title":"Cancers (Basel)"},{"key":"38996_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.trsl.2022.08.010","volume":"253","author":"M Bose","year":"2023","unstructured":"Bose, M. et al. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer. Transl Res. 253, 41\u201356 (2023).","journal-title":"Transl Res."},{"issue":"12","key":"38996_CR13","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41416-022-01747-0","volume":"126","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt\/\u03b2-catenin signalling pathway. Br. J. Cancer. 126 (12), 1684\u20131694 (2022).","journal-title":"Br. J. Cancer"},{"key":"38996_CR14","doi-asserted-by":"publisher","unstructured":"Multi-cohort validation of Ascore. an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer | Molecular Cancer | Full Text [Internet]. [cited 2024 Sep 5]. Available from: https:\/\/molecular-cancer.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12943-024-01945-9#Sec2","DOI":"10.1186\/s12943-024-01945-9#Sec2"},{"key":"38996_CR15","unstructured":"Identification and Validation of a Novel Anoikis-Related Gene Signature for Predicting Survival in Patients With Serous Ovarian Cancer - PubMed [Internet]. [cited 2024 Sep 5]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38274727\/"},{"issue":"D1","key":"38996_CR16","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44 (D1), D457\u2013D462 (2016).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"38996_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"38996_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4251\/wjgo.v8.i9.673","volume":"8","author":"WJ Shi","year":"2016","unstructured":"Shi, W. J. & Gao, J. B. Molecular mechanisms of chemoresistance in gastric cancer. World J. Gastrointest. Oncol. 8 (9), 673\u2013681 (2016).","journal-title":"World J. Gastrointest. Oncol."},{"key":"38996_CR19","unstructured":"High microsatellite instability. predicts good prognosis in intestinal-type gastric cancers - PubMed [Internet]. [cited 2024 Sep 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21332554\/"},{"issue":"3","key":"38996_CR20","doi-asserted-by":"publisher","first-page":"100034","DOI":"10.1016\/j.xcrm.2020.100034","volume":"1","author":"D Hsiehchen","year":"2020","unstructured":"Hsiehchen, D. et al. DNA repair gene mutations as predictors of immune checkpoint inhibitor response beyond tumor mutation burden. Cell. Rep. Med. 1 (3), 100034 (2020).","journal-title":"Cell. Rep. Med."},{"issue":"6439","key":"38996_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.aau0447","volume":"364","author":"R Mandal","year":"2019","unstructured":"Mandal, R. et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 364 (6439), 485\u2013491 (2019).","journal-title":"Science"},{"issue":"8","key":"38996_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/gcc.22468","volume":"56","author":"J Budczies","year":"2017","unstructured":"Budczies, J. et al. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes Cancer. 56 (8), 651\u2013659 (2017).","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"38996_CR23","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1158\/0008-5472.CAN-08-4596","volume":"69","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y. et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res. 69 (9), 3795\u20133801 (2009).","journal-title":"Cancer Res."},{"issue":"2","key":"38996_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","volume":"29","author":"N Niknafs","year":"2023","unstructured":"Niknafs, N. et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat. Med. 29 (2), 440\u2013449 (2023).","journal-title":"Nat. Med."},{"issue":"3","key":"38996_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/odi.14610","volume":"30","author":"X Ma","year":"2024","unstructured":"Ma, X. et al. FERMT2 upregulation in CAFs enhances EMT of OSCC and M2 macrophage polarization. Oral Dis. 30 (3), 991\u20131003 (2024).","journal-title":"Oral Dis."},{"issue":"6","key":"38996_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.2174\/1566524023666230529143837","volume":"24","author":"HB Chen","year":"2024","unstructured":"Chen, H. B. et al. ERK\/MAPK signalling pathway regulates MMP2 through ETS1 in renal clear cell carcinoma. Curr. Mol. Med. 24 (6), 780\u2013789 (2024).","journal-title":"Curr. Mol. Med."},{"key":"38996_CR27","doi-asserted-by":"publisher","first-page":"111179","DOI":"10.1016\/j.cellsig.2024.111179","volume":"120","author":"L Gao","year":"2024","unstructured":"Gao, L. et al. S100P facilitates LUAD progression via PKA\/c-Jun-mediated tumor-associated macrophage recruitment and polarization. Cell. Signal. 120, 111179 (2024).","journal-title":"Cell. Signal."},{"key":"38996_CR28","doi-asserted-by":"publisher","first-page":"154633","DOI":"10.1016\/j.prp.2023.154633","volume":"248","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Liu, S. S., Ma, J. & Qu, W. Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: mechanisms of action and clinical implications. Pathol. Res. Pract. 248, 154633 (2023).","journal-title":"Pathol. Res. Pract."},{"issue":"24","key":"38996_CR29","doi-asserted-by":"publisher","first-page":"e2309298","DOI":"10.1002\/advs.202309298","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. M2 Tumor-Associated Macrophages-Derived Exosomal MALAT1 promotes Glycolysis and gastric cancer progression. Adv. Sci. (Weinh). 11 (24), e2309298 (2024).","journal-title":"Adv. Sci. (Weinh)"},{"issue":"7","key":"38996_CR30","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.7150\/ijbs.41587","volume":"16","author":"Y Bai","year":"2020","unstructured":"Bai, Y. et al. Development and validation of a prognostic nomogram for gastric cancer based on DNA Methylation-Driven differentially expressed genes. Int. J. Biol. Sci. 16 (7), 1153\u20131165 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"38996_CR31","doi-asserted-by":"publisher","first-page":"1610643","DOI":"10.3389\/pore.2022.1610643","volume":"28","author":"J Zeng","year":"2022","unstructured":"Zeng, J. et al. A novel Glycolysis-Related long noncoding RNA signature for predicting overall survival in gastric cancer. Pathol. Oncol. Res. 28, 1610643 (2022).","journal-title":"Pathol. Oncol. Res."},{"key":"38996_CR32","unstructured":"Inference and analysis of cell-cell communication using CellChat - PubMed [Internet]. [cited 2024 Sep 9]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33597522\/"},{"issue":"12","key":"38996_CR33","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.4161\/cc.9.12.11989","volume":"9","author":"G Migneco","year":"2010","unstructured":"Migneco, G. et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell. Cycle. 9 (12), 2412\u20132422 (2010).","journal-title":"Cell. Cycle"},{"issue":"1","key":"38996_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-022-02300-w","volume":"41","author":"LF Gao","year":"2022","unstructured":"Gao, L. F. et al. Tumor bud-derived CCL5 recruits fibroblasts and promotes colorectal cancer progression via CCR5-SLC25A24 signaling. J. Exp. Clin. Cancer Res. 41 (1), 81 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"38996_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4161\/cbt.12.2.15734","volume":"12","author":"Y Zhao","year":"2011","unstructured":"Zhao, Y. et al. Systemic Par-4 inhibits non-autochthonous tumor growth. Cancer Biol. Ther. 12 (2), 152\u2013157 (2011).","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"38996_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/cancers13040697","volume":"13","author":"Y Sunami","year":"2021","unstructured":"Sunami, Y., B\u00f6ker, V. & Kleeff, J. Targeting and reprograming cancer-Associated fibroblasts and the tumor microenvironment in pancreatic cancer. Cancers (Basel). 13 (4), 697 (2021).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"38996_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13046-020-01611-0","volume":"39","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida, G. J. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J. Exp. Clin. Cancer Res. 39 (1), 112 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"38996_CR38","unstructured":"USP51\/ZEB1. \/ACTA2 axis promotes mesenchymal phenotype in gastric cancer and is associated with low cohesion characteristics - PubMed [Internet]. [cited 2024 Sep 10]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36603607\/"},{"issue":"11","key":"38996_CR39","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.3390\/cancers15113035","volume":"15","author":"S Demirkol Canli","year":"2023","unstructured":"Demirkol Canli, S. et al. A novel gene list identifies tumors with a Stromal-Mesenchymal phenotype and worse prognosis in gastric cancer. Cancers (Basel). 15 (11), 3035 (2023).","journal-title":"Cancers (Basel)"},{"key":"38996_CR40","unstructured":"LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation. and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy - PubMed [Internet]. [cited 2024 Sep 10]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38388484\/"},{"issue":"1","key":"38996_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41392-021-00784-0","volume":"6","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. GOLM1 exacerbates CD8\u2009+\u2009T cell suppression in hepatocellular carcinoma by promoting Exosomal PD-L1 transport into tumor-associated macrophages. Signal. Transduct. Target. Ther. 6 (1), 397 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"38996_CR42","unstructured":"Combined Assessment of the Tumor-Stroma Ratio. and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer - PubMed [Internet]. [cited 2024 Sep 10]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34831157\/"},{"issue":"3","key":"38996_CR43","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3390\/ijms24032805","volume":"24","author":"K Oura","year":"2023","unstructured":"Oura, K., Morishita, A., Hamaya, S., Fujita, K. & Masaki, T. The roles of epigenetic regulation and the tumor microenvironment in the mechanism of resistance to systemic therapy in hepatocellular carcinoma. Int. J. Mol. Sci. 24 (3), 2805 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"38996_CR44","doi-asserted-by":"crossref","unstructured":"Mahdi, W. A. et al. Effect of Europinidin against Alcohol-Induced Liver Damage in Rats by Inhibiting the TNF (2023). -\u03b1\/TGF-\u03b2\/IFN-\u03b3\/NF-kB\/Caspase-3 Signaling Pathway. ACS Omega. ;8(25):22656\u201364.","DOI":"10.1021\/acsomega.3c01312"},{"issue":"6","key":"38996_CR45","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.3168\/jds.2023-23465","volume":"107","author":"X Hao","year":"2024","unstructured":"Hao, X. et al. Thioredoxin-2 suppresses hydrogen peroxide-activated nuclear factor kappa B signaling via alleviating oxidative stress in bovine adipocytes. J. Dairy. Sci. 107 (6), 4045\u20134055 (2024).","journal-title":"J. Dairy. Sci."},{"issue":"2","key":"38996_CR46","first-page":"232","volume":"3","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Hays, E., Rama, M. & Bonavida, B. Cell-mediated immune resistance in cancer. Cancer Drug Resist. 3 (2), 232\u2013251 (2020).","journal-title":"Cancer Drug Resist."},{"key":"38996_CR47","doi-asserted-by":"publisher","first-page":"e80315","DOI":"10.7554\/eLife.80315","volume":"11","author":"A Gutwillig","year":"2022","unstructured":"Gutwillig, A. et al. Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. Elife 11, e80315 (2022).","journal-title":"Elife"},{"issue":"10","key":"38996_CR48","doi-asserted-by":"publisher","first-page":"8717","DOI":"10.3390\/ijms24108717","volume":"24","author":"S Kumar","year":"2023","unstructured":"Kumar, S. et al. Evolution of resistance to Irinotecan in cancer cells involves generation of Topoisomerase-Guided mutations in Non-Coding genome that reduce the chances of DNA breaks. Int. J. Mol. Sci. 24 (10), 8717 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"38996_CR49","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","volume":"36","author":"M Kartal-Yandim","year":"2016","unstructured":"Kartal-Yandim, M., Adan-Gokbulut, A. & Baran, Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit. Rev. Biotechnol. 36 (4), 716\u2013726 (2016).","journal-title":"Crit. Rev. Biotechnol."},{"issue":"5","key":"38996_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (5), 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"38996_CR51","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0327-7_16","volume":"2120","author":"G Sturm","year":"2020","unstructured":"Sturm, G., Finotello, F. & List, M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-Sequencing data. Methods Mol. Biol. 2120, 223\u2013232 (2020).","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"38996_CR52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods. 12 (5), 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"issue":"11","key":"38996_CR53","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28 (11), 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"38996_CR54","unstructured":"DeconstructSigs. delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution - PubMed [Internet]. [cited 2024 Sep 15]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26899170\/"},{"key":"38996_CR55","unstructured":"Comprehensive Integration of Single-Cell. Data - PubMed [Internet]. [cited 2024 Sep 15]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31178118\/"},{"issue":"7","key":"38996_CR56","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43 (7), e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"38996_CR57","unstructured":"The single-cell. transcriptional landscape of mammalian organogenesis - PubMed [Internet]. [cited 2024 Sep 15]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30787437\/"},{"issue":"1","key":"38996_CR58","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using cellchat. Nat. Commun. 12 (1), 1088 (2021).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38996-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38996-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38996-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:01:14Z","timestamp":1775599274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38996-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38996"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38996-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was based entirely on retrospective analyses of publicly available, de-identified transcriptomic and clinical datasets from multiple independent gastric cancer cohorts, such as TCGA and GEO. No new human participants were recruited and no additional human tissue samples were collected specifically for this study. All methods were carried out in accordance with relevant guidelines and regulations, including the principles of the Declaration of Helsinki. According to the institutional policies of Tianjin Medical University Cancer Institute and Hospital and the First Medical Center of Chinese PLA General Hospital, as well as national regulations, analyses using publicly available, anonymized data are considered exempt from human-subjects research review and do not require institutional review board (IRB) approval or informed consent. Therefore, no formal ethics committee approval or written informed consent was required for this study.Ethics approval and consent to participate","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants involved in this study provided informed consent. Their participation was entirely voluntary, and they were informed of their rights and the purpose of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"11571"}}